Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $183.63 on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares after it surveyed top market analysts. Calculating estimated earnings after taking into consideration different elements, it is predicted to come at $10.08 for the next fiscal and $N/A for underway quarter.
Analysts take into account the price to earnings ratio to estimate the firm’s valuation. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor. The formula to calculate ratio is stock’s latest price/ per share earnings. The P/E ratio of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stands at 21.92.
Analysts also work out Price/Earnings Growth ratio in an attempt to estimate the valuation of a firm. This ratio commonly known as the PEG ratio implies the stock’s valuation compared to earnings growth potential. Investors look to invest in the stocks with a lower PEG ratio. For Jazz Pharmaceuticals plc, the PEG ratio for coming 3-5 years is 0.70.
The technical analysis highlights that Jazz Pharmaceuticals plc current is trading $-16.00 points away or -11.37% from its 50-day moving average of $140.68. Further it is trading $-15.09 or -10.79% away its 200-day moving average of $139.77.
The 52-week high of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was $169.04 while lowest point recorded in 52-week was $108.50. It implies if stock price makes a movement of over $-44.36, it will record a new 52-week high. In the case of +14.91% drop, it will touch a new 52-week low.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...